Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Cook, Alistair M ^a,c   McDonnell, Alison M ^a,c   Lake, Richard A ^a,c   Nowak, Anna K ^a,b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c National Centre for Asbestos Related Diseases   (Australia)

Author keywords

dendritic cell; flow cytometry; glucocorticoid; Immunotherapy; lymphodepletion; mesothelioma; T cell; treg

Indexed keywords

ANTI CD40 AGONISTIC ANTIBODY; ANTIBODY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; INDUCIBLE T CELL COSTIMULATOR; KI 67 ANTIGEN; PEMETREXED; PLATINUM; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PLEURA MESOTHELIOMA; REGULATORY T LYMPHOCYTE;

EID: 84961613506     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1066062     Document Type: Article

References (75)

1. A.K.Nowak, B.W.S.Robinson, R.A.Lake. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63:4490-6; PMID:12907622
2. A.M.McDonnell, A.K.Nowak, R.A.Lake. Contribution of the immune system to the chemotherapeutic response. Semin Immunopathol 2011; 33:353-67; PMID:21274535; http://dx.doi.org/10.1007/s00281-011-0246-z
3. N.J.Vogelzang, J.J.Rusthoven, J.Symanowski, C.Denham, E.Kaukel, P.Ruffie, U.Gatzemeier, M.Boyer, S.Emri, C.Manegold et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-44; PMID:12860938; http://dx.doi.org/10.1200/JCO.2003.11.136
4. A.Shih, K.C.Jackson. Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother 2007; 21:69-76; PMID:18032321; http://dx.doi.org/10.1080/J354v21n04_14
5. C.Stahn, F.Buttgereit. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008; 4:525-33; PMID:18762788; http://dx.doi.org/10.1038/ncprheum0898
6. M.Kadmiel, J.A.Cidlowski. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 2013; 34:518-30; PMID:23953592; http://dx.doi.org/10.1016/j.tips.2013.07.003
7. M.Zen, M.Canova, C.Campana, S.Bettio, L.Nalotto, M.Rampudda, R.Ramonda, L.Iaccarino, A.Doria. The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011; 10:305-10; PMID:21224015; http://dx.doi.org/10.1016/j.autrev.2010.11.009
8. J.Gerdes, H.Lemke, H.Baisch, H.H.Wacker, U.Schwab, H.Stein. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133:1710-5; PMID:6206131
9. A.Hutloff, A.M.Dittrich, K.C.Beier, B.Eljaschewitsch, R.Kraft, I.Anagnostopoulos, R.A.Kroczek. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397:263-6; PMID:9930702; http://dx.doi.org/10.1038/16717
10. O.Acuto, F.Michel. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003; 3:939-51; PMID:14647476; http://dx.doi.org/10.1038/nri1248
11. D.A.Hildeman, Y.Zhu, T.C.Mitchell, P.Bouillet, A.Strasser, J.Kappler, P.Marrack. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 2002; 16:759-67; PMID:12121658; http://dx.doi.org/10.1016/S1074-7613(02)00322-9
12. J.D.Miller, R.G.van der Most, R.S.Akondy, J.T.Glidewell, S.Albott, D.Masopust, K.Murali-Krishna, P.L.Mahar, S.Edupuganti, S.Lalor et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28:710-22; PMID:18468462; http://dx.doi.org/10.1016/j.immuni.2008.02.020
13. A.Boltjes, F.Van Wijk. Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol 2014; 5:131; PMID:24744755; http://dx.doi.org/10.3389/fimmu.2014.00131
14. M.Collin, N.McGovern, M.Haniffa. Human dendritic cell subsets. Immunology 2013; 140:22-30; PMID:23621371; http://dx.doi.org/10.1111/imm.12117
15. V.I.Leussink, S.Jung, U.Merschdorf, K.V.Toyka, R.Gold. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001; 58:91-7; PMID:11176941; http://dx.doi.org/10.1001/archneur.58.1.91
16. R.V.Sionov, O.Cohen, S.Kfir, Y.Zilberman, E.Yefenof. Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis. J Exp Med 2006; 203:189-201; PMID:16390935; http://dx.doi.org/10.1084/jem.20050433
17. W.Zou. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295-307; PMID:16557261; http://dx.doi.org/10.1038/nri1806
18. M.J.McCoy, A.K.Nowak, R.G.van der Most, I.M.Dick, R.A.Lake. Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunol Immunother 2012; 62:529-39; PMID:23069871; http://dx.doi.org/10.1007/s00262-012-1360-z
19. A.M.Wolf, D.Wolf, M.Steurer, G.Gastl, E.Gunsilius, B.Grubeck-Loebenstein. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9:606-12; PMID:12576425
20. F.Ichihara, K.Kono, A.Takahashi, H.Kawaida, H.Sugai, H.Fujii. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9:4404-8; PMID:14555512
21. L.Liu, G.Wu, J.Yao, Q.Ding, S.Huang. CD4+CD25high regulatory cells in peripheral blood of cancer patients. Neuro Endocrinol Lett 2008; 29:240-5; PMID:18404145
22. U.K.Liyanage, T.T.Moore, H.Joo, Y.Tanaka, V.Herrmann, G.Doherty, J.A.Drebin, S.M.Strasberg, T.J.Eberlein, P.S.Goedegebuure et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-61; PMID:12193750; http://dx.doi.org/10.4049/jimmunol.169.5.2756
23. R.Okita, T.Saeki, S.Takashima, Y.Yamaguchi, T.Toge. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 2005; 14:1269-73; PMID:16211295
24. L.A.Ormandy, T.Hillemann, H.Wedemeyer, M.P.Manns, T.F.Greten, F.Korangy. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65:2457-64; PMID:15781662; http://dx.doi.org/10.1158/0008-5472.CAN-04-3232
25. F.Meloni, M.Morosini, N.Solari, F.Bini, P.Vitulo, E.Arbustini, C.Pellegrini, A.M.Fietta. Peripheral CD4+ CD25+ Treg cell expansion in lung transplant recipients is not affected by calcineurin inhibitors. Int Immunopharmacol 2006; 6:2002-10; PMID:17161354; http://dx.doi.org/10.1016/j.intimp.2006.07.019
26. A.M.Miller, K.Lundberg, V.Ozenci, A.H.Banham, M.Hellström, L.Egevad, P.Pisa. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177:7398-405; PMID:17082659; http://dx.doi.org/10.4049/jimmunol.177.10.7398
27. R.P.Petersen, M.J.Campa, J.Sperlazza, D.Conlon, M.Joshi, D.H.Harpole, E.F.Patz. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006; 107:2866-72; PMID:17099880; http://dx.doi.org/10.1002/cncr.22282
28. K.Shimizu, M.Nakata, Y.Hirami, T.Yukawa, A.Maeda, K.Tanemoto. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010; 5:585-90; PMID:20234320
29. T.J.Curiel, G.Coukos, L.Zou, X.Alvarez, P.Cheng, P.Mottram, M.Evdemon-Hogan, J.R.Conejo-Garcia, L.Zhang, M.Burow et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093
30. G.J.Bates, S.B.Fox, C.Han, R.D.Leek, J.F.Garcia, A.L.Harris, A.H.Banham. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-80; PMID:17135638; http://dx.doi.org/10.1200/JCO.2006.05.9584
31. G.Perrone, P.A.Ruffini, V.Catalano, C.Spino, D.Santini, M.Pietro, C.Spoto, C.Zingaretti, V.Sisti, P.Alessandroni et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008; 44:1875-82; PMID:18617393; http://dx.doi.org/10.1016/j.ejca.2008.05.017
32. N.Hiraoka, K.Onozato, T.Kosuge, S.Hirohashi. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12:5423-34; PMID:17000676; http://dx.doi.org/10.1158/1078-0432.CCR-06-0369
33. Q.Gao, S.Qiu, J.Fan, J.Zhou, X.Wang, Y.Xiao, Y.Xu, Y.Li, Z.Tang. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25:2586-93; PMID:17577038; http://dx.doi.org/10.1200/JCO.2006.09.4565
34. J.Zhou, T.Ding, W.Pan, L.Zhu, L.Li, L.Zheng. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 2009; 125:1640-8; PMID:19569243; http://dx.doi.org/10.1002/ijc.24556
35. E.S.Jordanova, A.Gorter, O.Ayachi, F.Prins, L.G.Durrant, G.G.Kenter, S.H.van der Burg, G.J.Fleuren. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 2008; 14:2028-2035; PMID:18381941; http://dx.doi.org/10.1158/1078-0432.CCR-07-4554
36. K.Koyama, H.Kagamu, S.Miura, T.Hiura, T.Miyabayashi, R.Itoh, H.Kuriyama, H.Tanaka, J.Tanaka, H.Yoshizawa et al. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008; 14:6770-9; PMID:18980970; http://dx.doi.org/10.1158/1078-0432.CCR-08-1156
37. E.Sato, S.H.Olson, J.Ahn, B.Bundy, H.Nishikawa, F.Qian, A.A.Jungbluth, D.Frosina, S.Gnjatic, C.Ambrosone et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102
38. X.Chen, T.Murakami, J.J.Oppenheim, O.M.Z.Howard. Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death. Eur J Immunol 2004; 34:859-69; PMID:14991616; http://dx.doi.org/10.1002/eji.200324506
39. U.Baschant, J.Tuckermann. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol 2010; 120:69-75; PMID:20346397; http://dx.doi.org/10.1016/j.jsbmb.2010.03.058
40. Y.Kang, L.Xu, W.Bin, A.Chen, G.Zheng. Cutting edge: immunosuppressant as adjuvant for tolerogenic immunization. J Immunol 2008; 180:5172-6; PMID:18390698; http://dx.doi.org/10.4049/jimmunol.180.8.5172
41. J.Pandolfi, P.Baz, P.Fernández, A.D.Lupi, F.Payaslián, L.A.Billordo, L.Fainboim, L.Arruvito. Regulatory and effector T-cells are differentially modulated by Dexamethasone. Clin Immunol 2013; 149:400-10; PMID:24211714; http://dx.doi.org/10.1016/j.clim.2013.09.008
42. A.Suárez, P.López, J.Gómez, C.Gutiérrez. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis 2006; 65:1512-7; http://dx.doi.org/10.1136/ard.2005.049924
43. J.Baba, S.Watanabe, Y.Saida, T.Tanaka, T.Miyabayashi, J.Koshio, K.Ichikawa, K.Nozaki, T.Koya, K.Deguchi et al. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 2012; 120:2417-27; PMID:22806892; http://dx.doi.org/10.1182/blood-2012-02-411124
44. F.J.Barrat, D.J.Cua, A.Boonstra, D.F.Richards, C.Crain, H.F.Savelkoul, R.de Waal-Malefyt, R.L.Coffman, C.M.Hawrylowicz, A.O'Garra. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002; 195:603-16; PMID:11877483; http://dx.doi.org/10.1084/jem.20011629
45. M.Sato, M.Liu, M.Anraku, T.Ogura, G.D'Cruz, B.A.Alman, T.K.Waddell, E.Kim, L.Zhang, S.Keshavjee. Allograft airway fibrosis in the pulmonary milieu: a disorder of tissue remodeling. Am J Transpl: Off J Am Soc Transpl Am Soc Transpl Surg 2008; 8:517-28; PMID:18294148; http://dx.doi.org/10.1111/j.1600-6143.2007.02106.x
46. B.J.Biller, A.Guth, J.H.Burton, S.W.Dow. Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J Vet Intern Med 2010; 24:1118-23; PMID:20666983; http://dx.doi.org/10.1111/j.1939-1676.2010.0557.x
47. F.Lechner, D.K.Wong, P.R.Dunbar, R.Chapman, R.T.Chung, P.Dohrenwend, G.Robbins, R.Phillips, P.Klenerman, B.D.Walker. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-512; PMID:10790425; http://dx.doi.org/10.1084/jem.191.9.1499
48. M.F.Callan, L.Tan, N.Annels, G.S.Ogg, J.D.Wilson, C.A.O'Callaghan, N.Steven, A.J.McMichael, A.B.Rickinson. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med 1998; 187:1395-402; PMID:9565632; http://dx.doi.org/10.1084/jem.187.9.1395
49. V.Appay, P.R.Dunbar, M.Callan, P.Klenerman, G.M.A.Gillespie, L.Papagno, G.S.Ogg, A.King, F.Lechner, C.A.Spina et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8:379-85; PMID:11927944; http://dx.doi.org/10.1038/nm0402-379
50. M.Cumberbatch, R.J.Dearman, I.Kimber. Inhibition by dexamethasone of Langerhans cell migration: influence of epidermal cytokine signals. Immunopharmacology 1999; 41:235-43; PMID:10428652; http://dx.doi.org/10.1016/S0162-3109(99)00037-5
51. L.Piemonti, P.Monti, P.Allavena, M.Sironi, L.Soldini, B.E.Leone, C.Socci, V.Di Carlo. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999; 162:6473-81; PMID:10352262
52. N.Vanderheyde, V.Verhasselt, M.Goldman, F.Willems. Inhibition of human dendritic cell functions by methylprednisolone. Transplantation 1999; 67:1342-7; PMID:10360588; http://dx.doi.org/10.1097/00007890-199905270-00009
53. T.Kitajima, K.Ariizumi, P.R.Bergstresser, A.Takashima. A novel mechanism of glucocorticoid-induced immune suppression: the inhibiton of T cell-mediated terminal maturation of a murine dendritic cell line. J Clin Invest 1996; 98:142-7; PMID:8690786; http://dx.doi.org/10.1172/JCI118759
54. M.Moser, T.De Smedt, T.Sornasse, F.Tielemans, A.A.Chentoufi, E.Muraille, M.Van Mechelen, J.Urbain, O.Leo. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. Eur J Immunol 1995; 25:2818–24; PMID:7589077; http://dx.doi.org/10.1002/eji.1830251016
55. M.Bros, F.Jährling, A.Renzing, N.Wiechmann, N.Dang, A.Sutter, R.Ross, J.Knop, S.Sudowe, A.B.Reske-Kunz. A newly established murine immature dendritic cell line can be differentiated into a mature state, but exerts tolerogenic function upon maturation in the presence of glucocorticoid. Blood 2007; 109:3820-9; PMID:17209058; http://dx.doi.org/10.1182/blood-2006-07-035576
56. L.C.Zaba, J.Fuentes-Duculan, R.M.Steinman, J.G.Krueger, M.A.Lowes. Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest 2007; 117:2517-25; PMID:17786242; http://dx.doi.org/10.1172/JCI32282
57. C.E.Angel, E.George, A.E.S.Brooks, L.L.Ostrovsky, H.La T.Brown, P.R.Dunbar. Cutting edge: CD1a+ antigen-presenting cells in human dermis respond rapidly to CCR7 ligands. J Immunol 2006; 176:5730-34; PMID:16670277; http://dx.doi.org/10.4049/jimmunol.176.10.5730
58. A.D.McLellan, A.Heiser, R.V.Sorg, D.B.Fearnley, D.N.Hart. Dermal dendritic cells associated with T lymphocytes in normal human skin display an activated phenotype. J Invest Dermatol 1998; 111:841-9; PMID:9804348; http://dx.doi.org/10.1046/j.1523-1747.1998.00375.x
59. M.Röllinghoff, A.Starzinski-Powitz, K.Pfizenmaier, H.Wagner. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med 1977; 145:455-9; PMID:299883; http://dx.doi.org/10.1084/jem.145.2.455
60. M.Glaser. Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide. Cell Immunol 1979; 48:339-45; PMID:228870; http://dx.doi.org/10.1016/0008-8749(79)90128-X
61. S.Yoshida, K.Nomoto, K.Himeno, K.Takeya. Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamide-treated mice. Clin Exp Immunol 1979; 38:211-7; PMID:527259
62. S.Man, G.Bocci, G.Francia, S.K.Green, S.Jothy, D.Hanahan, P.Bohlen, D.J.Hicklin, G.Bergers, R.S.Kerbel. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002; 62:2731-5; PMID:12019144
63. D.Hanahan, G.Bergers, E.Bergsland. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105:1045-7; PMID:10772648; http://dx.doi.org/10.1172/JCI9872
64. T.Browder, C.E.Butterfield, B.M.Kräling, B.Shi, B.Marshall, M.S.O'Reilly, J.Folkman. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-86; PMID:10766175
65. M.Tongu, N.Harashima, H.Monma, T.Inao, T.Yamada, H.Kawauchi, M.Harada. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immun 2012; 62:383-91; http://dx.doi.org/10.1007/s00262-012-1343-0
66. D.Berd, M.J.Mastrangelo. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res 1988; 48:1671-75; PMID:2830969
67. F.Ghiringhelli, C.Menard, P.E.Puig, S.Ladoire, S.Roux, F.Martin, E.Solary, A.Le Cesne, L.Zitvogel, B.Chauffert. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol, Immunother: CII 2007; 56:641-8; PMID:16960692; http://dx.doi.org/10.1007/s00262-006-0225-8
68. F.Ghiringhelli, L.Apetoh, F.Housseau, G.Kroemer, L.Zitvogel. Links between innate and cognate tumor immunity. Curr Opin Immunol 2007; 19:224-31; PMID:17303400; http://dx.doi.org/10.1016/j.coi.2007.02.003
69. S.Rutella, S.Danese, G.Leone. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006; 108:1435-40; PMID:16684955; http://dx.doi.org/10.1182/blood-2006-03-006403
70. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63:4490-6; PMID:12907622
71. A.Khong, D.J.Nelson, A.K.Nowak, R.A.Lake, B.W.S.Robinson. The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol 2012; 31:246-66; PMID:22804570; http://dx.doi.org/10.3109/08830185.2012.698338
72. M.K.Matyszak, S.Citterio, M.Rescigno, P.Ricciardi-Castagnoli. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur J Immunol 2000; 30:1233-42; PMID:10760813; http://dx.doi.org/10.1002/(SICI)1521-4141(200004)30:4%3c1233::AID-IMMU1233%3e3.0.CO;2-F
73. M.Löwenberg, A.P.Verhaar, J.Bilderbeek, J.van Marle, F.Buttgereit, M.P.Peppelenbosch, S.J.van Deventer, D.W.Hommes. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep 2006; 7:1023-9; PMID:16888650; http://dx.doi.org/10.1038/sj.embor.7400775
74. M.W.Harr, Y.Rong, M.D.Bootman, H.L.Roderick, C.W.Distelhorst. Glucocorticoid-mediated inhibition of Lck modulates the pattern of T cell receptor-induced calcium signals by down-regulating inositol 1,4,5-trisphosphate receptors. J Biol Chem 2009; 284:31860-71; PMID:19776014; http://dx.doi.org/10.1074/jbc.M109.005579
75. M.J.Byrne, A.K.Nowak. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15:257-60; PMID:14760119; http://dx.doi.org/10.1093/annonc/mdh059